Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar 26;70(5):513-28.
doi: 10.2165/11533070-000000000-00000.

Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence

Richard Dodel  1 , Frauke Neff, Carmen Noelker, Refik Pul, Yansheng Du, Michael Bacher, Wolfgang Oertel
Affiliations
Review

Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence

Richard Dodel et al. Drugs. .

Abstract

Current treatment options for Alzheimer's disease (AD) exert only a short-lived effect on disease symptoms. Active and passive immunotherapy have both been shown to be effective in clearing plaques, removing beta-amyloid (Abeta) and improving behaviour in animal models of AD. Although the first active immunization trial in humans was discontinued because of severe adverse effects, several new approaches are currently being investigated in clinical trials. Recently, commercially available intravenous immunoglobulins (IVIG) have been used in small pilot trials for the treatment of patients with AD, based on the hypothesis that IVIG contains naturally occurring autoantibodies (nAbs-Abeta) that specifically recognize and block the toxic effects of Abeta. Furthermore, these nAbs-Abeta are reduced in AD patients compared with healthy controls, supporting the notion of replacement with IVIG. Beyond the occurrence of nAbs-Abeta, evidence for several other mechanisms associated with IVIG in AD has been reported in preclinical experiments and clinical studies. In 2009, a phase III clinical trial involving more than 360 AD patients was initiated and may provide conclusive evidence for the effect of IVIG as a treatment option for AD in 2011. In this article, we review the current knowledge and scientific rationale for using IVIG in patients with AD and other neurodegenerative disorders.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nat Med. 2006 Jun;12(6):688-92 - PubMed
    1. Autoimmun Rev. 2007 Mar;6(4):257-9 - PubMed
    1. Pediatr Allergy Immunol. 2006 Feb;17(1):60-8 - PubMed
    1. J Clin Invest. 2005 Sep;115(9):2423-33 - PubMed
    1. Br J Haematol. 2006 Oct;135(1):97-100 - PubMed

MeSH terms

LinkOut - more resources